Severity: Warning
Message: file_get_contents(https://...@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
Filename: helpers/my_audit_helper.php
Line Number: 176
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 176
Function: file_get_contents
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 250
Function: simplexml_load_file_from_url
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3122
Function: getPubMedXML
File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global
File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword
File: /var/www/html/index.php
Line: 316
Function: require_once
Gefitinib/Quantum dots (QDs) loaded peptide long circulating liposomes (G/QDs-P-LCPL) were successfully prepared for treatment and detection by fluorescence labeling for nasopharyngeal carcinoma. Gefitinib was found to have marked inhibition which is dose- and time-dependent. Hoechst 33258 florescence staining and wound-healing assay indicated that as G/QDs-P-LCPL concentration increased, HONE1 staining cells decreased, while the amount of nucleus pyknosis and karyorrhexis grew. Florescence tracing result shows that the drug mainly distributed through tumors. G-P-LCPL target the HONE1 cells and significantly increase the drug uptake efficiency so as to improve the cells inhibit rate compared with the non-targeting group. The EGFR peptide LCPL are potentially useful for drug and fluorescence labeled delivery applications.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.bbrc.2017.06.011 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!